Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tigatuzumab + gemcitabine in pancreatic cancer
NCT00521404Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2007
- Primary completion
- Aug 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tigatuzumab in pancreatic cancer (PC), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Progression-Free Survival Rate at 16 weeks. Started Aug 2007; status: completed.
02
Drugs
tigatuzumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00521404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00521404.